menu
    • menu

    Find Deutetrabenazine manufacturers, exporters & distributors on PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Farmhispania Deutetrabenazine

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    10

    API Suppliers

    API Suppliers

    6

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    1

    KDMF

    KDMF

    6

    NDC API

    NDC API

    0

    VMF

    NDC API

    7

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 35,341

    MARKET PLACE

    3

    API

    0

    FDF

    4INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    14

    FDF Dossiers

    FDF Dossiers

    14

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    9DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    304

    US Patents

    12

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    29

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    890,369,750

    Annual Reports

    4,243

    Finished Drug Prices

    NA

    153 RELATED EXCIPIENT COMPANIES

    275EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Deutetrabenazine, Dutetrabenazine, P341g6w9nb, Sd-809, (3rs,11brs)-9,10-di((2h3)methoxy)-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizin-2-one, 2h-benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-, (3r,11br)-rel-
    Molecular Formula
    C19H27NO3
    Molecular Weight
    323.5  g/mol
    InChI Key
    MKJIEFSOBYUXJB-WEZHFFAMSA-N
    FDA UNII
    P341G6W9NB
    Deutetrabenazine
    Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntingtons disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844]. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions. Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission. Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release. As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease. In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo. It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.
    1 2D Structure

    Deutetrabenazine

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3S,11bS)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
    2.1.2 InChI
    InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m0/s1/i3D3,4D3
    2.1.3 InChI Key
    MKJIEFSOBYUXJB-WEZHFFAMSA-N
    2.1.4 Canonical SMILES
    CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
    2.1.5 Isomeric SMILES
    [2H]C([2H])([2H])OC1=C(C=C2[C@@H]3CC(=O)[C@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
    2.2 Other Identifiers
    2.2.1 UNII
    P341G6W9NB
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Deutetrabenazine

    2.3.2 Depositor-Supplied Synonyms

    1. Deutetrabenazine

    2. Dutetrabenazine

    3. P341g6w9nb

    4. Sd-809

    5. (3rs,11brs)-9,10-di((2h3)methoxy)-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizin-2-one

    6. 2h-benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-, (3r,11br)-rel-

    7. Sd809

    8. Unii-p341g6w9nb

    9. Deutetrabenazine [usan:inn]

    10. Sd 809

    11. Deutetrabenazine [usan]

    12. Deutetrabenazine [inn]

    13. Schembl16228022

    14. Hsdb 8414

    15. Deutetrabenazine [who-dd]

    16. Deutetrabenazine [orange Book]

    17. At21717

    18. Db12161

    2.4 Create Date
    2014-04-28
    3 Chemical and Physical Properties
    Molecular Weight 323.5 g/mol
    Molecular Formula C19H27NO3
    XLogP32.9
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count4
    Exact Mass323.23675420 g/mol
    Monoisotopic Mass323.23675420 g/mol
    Topological Polar Surface Area38.8 Ų
    Heavy Atom Count23
    Formal Charge0
    Complexity425
    Isotope Atom Count6
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameAUSTEDO
    Active IngredientDEUTETRABENAZINE
    CompanyTEVA BRANDED PHARM (Application Number: N208082. Patents: 8524733, 9233959, 9296739, 9550780, 9814708)

    4.2 Therapeutic Uses

    Adrenergic Uptake Inhibitors

    National Library of Medicine's Medical Subject Headings. Deutetrabenazine. Online file (MeSH, 2018). Available from, as of April 5, 2018: https://meshb.nlm.nih.gov/search

    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Dutetrabenazine is included in the database.

    NIH/NLM; ClinicalTrials.Gov. Available from, as of April 5, 2018: https://clinicaltrials.gov/

    Austedo is indicated for the treatment of chorea associated with Huntington's disease. /Included in US product label/

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    Austedo is indicated for the treatment of tardive dyskinesia in adults. /Included in US product label/

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    /EXPL THER/ Deutetrabenazine, an inhibitor of vesicular monoamine transporter type 2 (VMAT2) depletes presynaptic dopamine and is useful in the treatment of hyperkinetic movement disorders. This study explored the safety, tolerability, and preliminary efficacy of deutetrabenazine in adolescents with moderate-to-severe tics associated with Tourette syndrome (TS). In this open-label study of 12-18-year-old patients with TS-related tics, deutetrabenazine was titrated up to 36 mg/day over 6 weeks to adequately suppress tics without bothersome adverse effects (AEs), followed by maintenance at optimal dose for 2 weeks. An independent blinded rater assessed tic severity using the Yale Global Tic Severity Scale (YGTSS), which was the primary outcome measure. Secondary outcome measures included the TS Clinical Global Impression (TS-CGI) and TS Patient Global Impression of Change (TS-PGIC). Twenty-three enrolled patients received deutetrabenazine and had at least 1 post-baseline YGTSS assessment. The mean (SD [standard deviation]) baseline YGTSS Total Tic Severity Score (TTS) was 31.6 (7.9) and had decreased by 11.6 (8.2) points at week 8, a 37.6% reduction in tic severity (p<0.0001). The TS-CGI score improved by 1.2 (0.81) points (p<0.0001) and the TS-PGIC results at week 8 indicated that 76% of patients were much improved or very much improved compared with baseline. The mean (SD) daily deutetrabenazine dose at week 8 was 32.1 (6.6) mg (range 18-36 mg). One week after withdrawal of deutetrabenazine, the TTS scores increased by 5.6 (8.4) points, providing confirmation of the drug effect. No serious or severe adverse events were reported. The results of this open-label 8-week study suggest that deutetrabenazine is safe and associated with improvement in tic severity in adolescents with TS and troublesome tics.

    PMID:27917309 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133390 Jankovic J et al; Tremor Other Hyperkinet Mov (N Y). 6: 422 (2016)

    4.3 Drug Warning

    /BOXED WARNING/ WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON'S DISEASE. Austedo can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of Austedo must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington's disease. Austedo is contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    Huntington's disease is a progressive disorder characterized by changes in mood, cognition, chorea, rigidity, and functional capacity over time. Vesicular monoamine transporter 2 (VMAT2) inhibitors, including deutetrabenazine, may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically reevaluate the need for deutetrabenazine in their patients by assessing the effect on chorea and possible adverse effects, including sedation/somnolence, depression and suicidality, parkinsonism, akathisia, restlessness, and cognitive decline. It may be difficult to distinguish between adverse reactions and progression of the underlying disease; decreasing the dose or stopping the drug may help the clinician to distinguish between the two possibilities. In some patients, the underlying chorea itself may improve over time, decreasing the need for deutetrabenazine.

    American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017

    Deutetrabenazine may increase the risk of akathisia, agitation, and restlessness in patients with Huntington's disease and tardive dyskinesia. In a 12-week, double-blind, placebo-controlled trial in Huntington's disease patients, akathisia, agitation, or restlessness was reported by 4% of patients treated with deutetrabenazine, compared to 2% of patients on placebo; in patients with tardive dyskinesia, 2% of patients treated with deutetrabenazine and 1% of patients on placebo experienced these events. Patients receiving deutetrabenazine should be monitored for signs and symptoms of restlessness and agitation, as these may be indicators of developing akathisia. If a patient develops akathisia during treatment with deutetrabenazine, the deutetrabenazine dose should be reduced; some patients may require discontinuation of therapy.

    American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017

    A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. While NMS has not been observed in patients receiving deutetrabenazine, it has been observed in patients receiving tetrabenazine (a closely related VMAT2 inhibitor). Clinicians should be alerted to the signs and symptoms associated with NMS. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria, rhabdomyolysis, and acute renal failure. The diagnosis of NMS can be complicated; other serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal disorders can present with similar signs and symptoms. Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. /Tetrabenazine/

    American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017

    For more Drug Warnings (Complete) data for Deutetrabenazine (14 total), please visit the HSDB record page.

    4.4 Drug Indication

    Indicated for the treatment of chorea associated with Huntingtons disease.

    FDA Label

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    In clinical trials, there was an evidence of clinical effectiveness of deutetrabenazine in improving the symptoms of involuntary movements in patient with tardive dyskinesia by reducing the mean Abnormal Involuntary Movement Scale (AIMS) score. In a randomized, double-blind, placebo-controlled crossover study in healthy male and female subjects, single dose administration of 24 mg deutetrabenazine results in an approximately 4.5 msec mean increase in QTc. Effects at higher exposures to deutetrabenazine or its metabolites have not been evaluated. Deutetrabenazine and its metabolites were shown to bind to melanin-containing tissues including eyes, skin and fur in pigmented rats. After a single oral dose of radiolabeled deutetrabenazine, radioactivity was still detected in eye and fur at 35 days following dosing.

    5.2 ATC Code

    N - Nervous system

    N07 - Other nervous system drugs

    N07X - Other nervous system drugs

    N07XX - Other nervous system drugs

    N07XX16 - Deutetrabenazine

    5.3 Absorption, Distribution and Excretion

    Absorption

    The extent of absorption is 80% with oral deutetrabenazine. As deutetrabenazine is extensively metabolized to its main active metabolites following administration, linear dose dependence of peak plasma concentrations (Cmax) and AUC was observed for the metabolites after single or multiple doses of deutetrabenazine (6 mg to 24 mg and 7.5 mg twice daily to 22.5 mg twice daily). Cmax of deuterated -HTBZ and -HTBZ are reached within 3-4 hours post-dosing. Food may increase the Cmax of -HTBZ or -HTBZ by approximately 50%, but is unlikely to have an effect on the AUC.

    Route of Elimination

    Deutetrabenazine is mainly excreted in the urine as metabolites. In healthy subjects, about 75% to 86% of the deutetrabenazine dose was excreted in the urine, and fecal recovery accounted for 8% to 11% of the dose. Sulfate and glucuronide conjugates of the -HTBZ and -HTBZ, as well as products of oxidative metabolism, accounted for the majority of metabolites in the urine. -HTBZ and -HTBZ metabolites accounted for less than 10% of the administered dose in the urine.

    Volume of Distribution

    The median volume of distribution (Vc/F) of the -HTBZ, and the -HTBZ metabolites of deutetrabenazine are approximately 500 L and 730 L, respectively. Human PET-scans of tetrabenazine indicate rapid distribution to the brain, with the highest binding in the striatum and lowest binding in the cortex. Similar distribution pattern is expected for deutetrabenazine.

    Clearance

    In patients with Huntington's disease, the median clearance values (CL/F) of the -HTBZ, and the -HTBZ metabolites of deutetrabenazine are approximately 47 L/hour and 70 L/hour, respectively.

    Results of PET-scan studies in humans show that following intravenous injection of (11)C-labeled tetrabenazine or alpha-dihydrotetrabenazine, radioactivity is rapidly distributed to the brain, with the highest binding in the striatum and lowest binding in the cortex.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    Following oral administration of deutetrabenazine, the extent of absorption is at least 80%.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    In a mass balance study in 6 healthy subjects, 75% to 86% of the deutetrabenazine dose was excreted in the urine, and fecal recovery accounted for 8% to 11% of the dose. Urinary excretion of the alpha-dihydrotetrabenazine and beta-dihydrotetrabenazine metabolites from deutetrabenazine each accounted for less than 10% of the administered dose. Sulfate and glucuronide conjugates of the alpha-dihydrotetrabenazine and beta-dihydrotetrabenazine metabolites of deutetrabenazine, as well as products of oxidative metabolism, accounted for the majority of metabolites in the urine.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    Austedo is primarily renally eliminated in the form of metabolites.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    5.4 Metabolism/Metabolites

    Deutetrabenazine undergoes extensive hepatic biotransformation mediated by carbonyl reductase to form its major active metabolites, -HTBZ and -HTBZ. These metabolites may subsequently metabolized to form several minor metabolites, with major contribution of CYP2D6 and minor contributions of CYP1A2 and CYP3A4/5.

    In a mass balance study in 6 healthy subjects, 75% to 86% of the deutetrabenazine dose was excreted in the urine, and fecal recovery accounted for 8% to 11% of the dose. Urinary excretion of the alpha-dihydrotetrabenazine and beta-dihydrotetrabenazine metabolites from deutetrabenazine each accounted for less than 10% of the administered dose. Sulfate and glucuronide conjugates of the alpha-dihydrotetrabenazine and beta-dihydrotetrabenazine metabolites of deutetrabenazine, as well as products of oxidative metabolism, accounted for the majority of metabolites in the urine.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    In vitro experiments in human liver microsomes demonstrate that deutetrabenazine is extensively biotransformed, mainly by carbonyl reductase, to its major active metabolites, alpha-dihydrotetrabenazine and beta-dihydrotetrabenazine, which are subsequently metabolized primarily by CYP2D6, with minor contributions of CYP1A2 and CYP3A4/5, to form several minor metabolites.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    5.5 Biological Half-Life

    The half-life of total (+)-HTBZ from deutetrabenazine is approximately 9 to 10 hours.

    The half-life of total (alpha+beta)-dihydrotetrabenazine from deutetrabenazine is approximately 9 to 10 hours.

    NIH; DailyMed. Current Medication Information for Austedo (Deutetrabenazine) Tablet, Coated (Updated: September 11, 2017). Available from, as of April 5, 2018: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0

    5.6 Mechanism of Action

    The precise mechanism of action of deutetrabenazine in mediating its anti-chorea effects is not fully elucidated. Deutetrabenazine reversibly depletes the levels of monoamines, such as dopamine, serotonin, norepinephrine, and histamine, from nerve terminals via its active metabolites. The major circulating metabolites are -dihydrotetrabenazine [HTBZ] and -HTBZ that act as reversible inhibitors of VMAT2. Inhibition of VMAT2 results in decreased uptake of monoamines into synaptic terminal and depletion of monoamine stores from nerve terminals. Deutetrabenazine contains the molecule deuterium, which is a naturally-occurring, nontoxic hydrogen isotope but with an increased mass relative to hydrogen. Placed at key positions, deuterium forms a stronger hydrogen bond with carbon that requires more energy for cleavage, thus attenuating CYP2D6-mediated metabolism without having any effect on the therapeutic target.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"DEUTETRABENAZINE","year":"2021","qtr":"Q1","strtotime":1616005800,"product":"DEUTETRABENAZINE (GROUP:C) (TAX INV NO:6 500205132 DT:13.03.2021","address":"PLOT NO.C-24, MNS HOUSE, INDUSTRIAL ESTATE, SANATH NAGAR,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"INCEPTA PHARMACEUTICALS LTD","customerCountry":"BANGLADESH","quantity":"0.35","actualQuantity":"0.35","unit":"KGS","unitRateFc":"49937.5","totalValueFC":"17297.7","currency":"USD","unitRateINR":3598000,"date":"18-Mar-2021","totalValueINR":"1259300","totalValueInUsd":"17297.7","indian_port":"HYDERABAD AIR","hs_no":"29029090","bill_no":"9462376","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24, MNS HOUSE, INDUSTRIAL ESTATE, SANATH NAGAR,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710786600,"product":"DEUTETRABENAZINE","address":"PLOT NO.C-24, MNS HOUSE,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"INCEPTA PHARMACEUTICAL LTD","customerCountry":"BANGLADESH","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"44000","totalValueFC":"43403","currency":"USD","unitRateINR":3604000,"date":"19-Mar-2024","totalValueINR":"3604000","totalValueInUsd":"43403","indian_port":"Hyderabad Air","hs_no":"29029090","bill_no":"8432009","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MNS HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691346600,"product":"DEUTETRABENAZINE. B\/N: 3136300001. MANUFACTURING . DT. JUL-2023 RE-TESTDT. JUL-2026.TL NO.: TL\/AZ\/22\/002977 DT. 04\/11\/2022","address":"SUR. NO. 377\/1B, BS. UDHYAN BUNGLOW,OFF. SG HIGHWAY, ISCON CROSS ROADAHMEDABAD,GUJARAT","city":"NA","supplier":"FARMHISPANIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"XYLOPIA LABS PRIVATE ","customerCountry":"INDIA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"35000","totalValueFC":"8813","currency":"USD","unitRateINR":"2890946.5","date":"07-Aug-2023","totalValueINR":"730037","totalValueInUsd":"8813","indian_port":"AHEMDABAD AIR","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SUR. NO. 377\/1B, BS. UDHYAN BUNGLOW,OFF. SG HIGHWAY, ISCON CROSS ROADAHMEDABAD,GUJARAT"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698604200,"product":"DEUTETRABENAZINE MICRONIZADA I. 31363. B\/N: 3136300002. MFG.DT. SEP-2023 RE-TEST DT. SEP-2026","address":"SUR. NO. 377\/1B, BS. UDHYAN BUNGLO","city":"AHMEDABAD,GUJARAT","supplier":"FARMHISPANIA","supplierCountry":"SPAIN","foreign_port":"BARCELONA","customer":"XYLOPIA LABS PRIVATE ","customerCountry":"INDIA","quantity":"0.79","actualQuantity":"0.789","unit":"KGS","unitRateFc":"35000","totalValueFC":"27937.1","currency":"USD","unitRateINR":"2947000","date":"30-Oct-2023","totalValueINR":"2325183","totalValueInUsd":"27937.1","indian_port":"Ahmedabad Air","hs_no":"29419090","bill_no":"8535155","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"BARCELONA","supplierAddress":"PASSEIG RIU BESOS, 9-10-08160 MONTMELO ESPANA, SPAINSDNF SPAIN","customerAddress":"SUR. NO. 377\/1B, BS. UDHYAN BUNGLO"}]
    18-Mar-2021
    19-Mar-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Granulation

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search